Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib plus fulvestrant in endocrine-resistant HER2-negative, hormone receptor-positive advanced breast cancer
2011-001230-42Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Dovitinib + fulvestrant with Placebo + fulvestrant (2 arms). Primary endpoint: Progression-Free Survival. Started Jan 2012; status: completed.
02
Drugs
dovitinibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-001230-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001230-42.